Download PDF
Semin Liver Dis 2006; 26(1): 052-061
DOI: 10.1055/s-2006-933563
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

The Medical Management of Primary Sclerosing Cholangitis

Susan N. Cullen1 , Roger W. Chapman2
  • 1Wycombe General Hospital, High Wycombe, United Kingdom
  • 2John Radcliffe Hospital, Oxford, United Kingdom
Further Information

Publication History

Publication Date:
23 February 2006 (online)

    Permissions and Reprints

ABSTRACT

Primary sclerosing cholangitis raises several challenges for the physician. These include the identification of a drug regimen that slows or reverses the progression of the disease, the effective management of the symptoms of cholestasis, and the prevention of complications of the disease, including the development of colorectal cancer. The most studied drug in PSC is ursodeoxycholic acid, which, despite a range of potentially valuable actions on the cholestatic liver, has not yet been proven to make a substantial change in the course of the disease. However, it may yet prove to be sufficiently effective in the prevention of colorectal neoplasia to be prescribable for this reason alone. Better progress has been made in identifying agents that can alleviate pruritus and prevent the progression of osteopenia.

KEYWORDS

Ursodeoxycholic acid - cholestasis - apoptosis - pruritus - osteoporosis

REFERENCES

  • 1 Poupon R E, Lindor K D, Cauch-Dudek K, Dickson E R, Poupon R, Heathcote E J. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis.  Gastroenterology. 1997;  113 884-890
    CrossrefPubMedGoogle Scholar
  • 2 Palma J, Reyes H, Ribalta J et al.. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo.  J Hepatol. 1997;  27 1022-1028
    CrossrefPubMedGoogle Scholar
  • 3 Mazzella G, Rizzo N, Azzaroli F et al.. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers.  Hepatology. 2001;  33 504-508
    CrossrefPubMedGoogle Scholar
  • 4 Colombo C, Battezzati P M, Podda M, Bettinardi N, Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.  Hepatology. 1996;  23 1484-1490
    PubMedGoogle Scholar
  • 5 Jacquemin E, Hermans D, Myara A et al.. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis.  Hepatology. 1997;  25 519-523
    CrossrefPubMedGoogle Scholar
  • 6 Essell J H, Schroeder M T, Harman G S et al.. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial.  Ann Intern Med. 1998;  128 975-981
    PubMedGoogle Scholar
  • 7 Lazaridis K N, Gores G J, Lindor K D. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’.  J Hepatol. 2001;  35 134-146
    CrossrefPubMedGoogle Scholar
  • 8 Crosignani A, Setchell K D, Invernizzi P, Larghi A, Rodrigues C M, Podda M. Clinical pharmacokinetics of therapeutic bile acids.  Clin Pharmacokinet. 1996;  30 333-358
    CrossrefPubMedGoogle Scholar
  • 9 Hempfling W, Dilger K, Beuers U. Systematic review: ursodeoxycholic acid-adverse effects and drug interactions.  Aliment Pharmacol Ther. 2003;  18 963-972
    CrossrefPubMedGoogle Scholar
  • 10 Hofmann A F. Pharmacology of ursodeoxycholic acid, an enterohepatic drug.  Scand J Gastroenterol Suppl. 1994;  204 1-15
    PubMedGoogle Scholar
  • 11 Beuers U, Fischer S, Spengler U, Paumgartner G. Formation of iso-ursodeoxycholic acid during administration of ursodeoxycholic acid in man.  J Hepatol. 1991;  13 97-103
    CrossrefPubMedGoogle Scholar
  • 12 Rost D, Rudolph G, Kloeters-Plachky P, Stiehl A. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.  Hepatology. 2004;  40 693-698
    CrossrefPubMedGoogle Scholar
  • 13 van de Meeberg P C, Wolfhagen F H, Van Berge-Henegouwen G P et al.. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.  J Hepatol. 1996;  25 887-894
    CrossrefPubMedGoogle Scholar
  • 14 Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.  Hepatology. 2002;  36 525-531
    CrossrefPubMedGoogle Scholar
  • 15 Guicciardi M E, Gores G J. Ursodeoxycholic acid cytoprotection: dancing with death receptors and survival pathways.  Hepatology. 2002;  35 971-973
    CrossrefPubMedGoogle Scholar
  • 16 Patel T, Gores G J. Apoptosis and hepatobiliary disease.  Hepatology. 1995;  21 1725-1741
    CrossrefPubMedGoogle Scholar
  • 17 Qiao L, Yacoub A, Studer E et al.. Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes.  Hepatology. 2002;  35 779-789
    CrossrefPubMedGoogle Scholar
  • 18 Rodrigues C M, Steer C J. Mitochondrial membrane perturbations in cholestasis.  J Hepatol. 2000;  32 135-141
    PubMedGoogle Scholar
  • 19 Rodrigues C M, Fan G, Ma X, Kren B T, Steer C J. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation.  J Clin Invest. 1998;  101 2790-2799
    CrossrefPubMedGoogle Scholar
  • 20 Smit J J, Schinkel A H, Oude Elferink R P et al.. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease.  Cell. 1993;  75 451-462
    CrossrefPubMedGoogle Scholar
  • 21 Van Nieuwkerk C M, Elferink R P, Groen A K et al.. Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene.  Gastroenterology. 1996;  111 165-171
    PubMedGoogle Scholar
  • 22 Alpini G, Baiocchi L, Glaser S et al.. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha.  Hepatology. 2002;  35 1041-1052
    CrossrefPubMedGoogle Scholar
  • 23 Kitani K, Ohta M, Kanai S. Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat.  Am J Physiol. 1985;  248 G407-G417
    PubMedGoogle Scholar
  • 24 Beuers U, Nathanson M H, Isales C M, Boyer J L. Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis.  J Clin Invest. 1993;  92 2984-2993
    PubMedGoogle Scholar
  • 25 Heuman D M, Mills A S, McCall J, Hylemon P B, Pandak W M, Vlahcevic Z R. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat.  Gastroenterology. 1991;  100 203-211
    PubMedGoogle Scholar
  • 26 Kitani K, Kanai S, Sato Y, Ohta M. Tauro alpha-muricholate is as effective as tauro beta-muricholate and tauroursodeoxycholate in preventing taurochenodeoxycholate-induced liver damage in the rat.  Hepatology. 1994;  19 1007-1012
    CrossrefPubMedGoogle Scholar
  • 27 Jazrawi R P, de Caestecker J S, Goggin P M et al.. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.  Gastroenterology. 1994;  106 134-142
    PubMedGoogle Scholar
  • 28 Stiehl A, Rudolph G, Sauer P, Theilmann L. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.  J Hepatol. 1995;  23 283-289
    PubMedGoogle Scholar
  • 29 Beuers U, Bilzer M, Chittattu A et al.. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver.  Hepatology. 2001;  33 1206-1216
    CrossrefPubMedGoogle Scholar
  • 30 Fickert P, Zollner G, Fuchsbichler A et al.. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver.  Gastroenterology. 2001;  121 170-183
    CrossrefPubMedGoogle Scholar
  • 31 Kurz A K, Graf D, Schmitt M, Vom Dahl S, Haussinger D. Tauroursodeoxycholate-induced choleresis involves p38(MAPK) activation and translocation of the bile salt export pump in rats.  Gastroenterology. 2001;  121 407-419
    CrossrefPubMedGoogle Scholar
  • 32 Borum M, Fromm H. Expression of HLA molecules on hepatocytes: does ursodeoxycholic acid prevent immunologic injury?.  Gastroenterology. 1990;  99 561-562
    PubMedGoogle Scholar
  • 33 Terasaki S, Nakanuma Y, Ogino H, Unoura M, Kobayashi K. Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy.  Am J Gastroenterol. 1991;  86 1194-1199
    PubMedGoogle Scholar
  • 34 Bergamini A, Dini L, Baiocchi L et al.. Bile acids with differing hydrophilic-hydrophobic properties do not influence cytokine production by human monocytes and murine Kupffer cells.  Hepatology. 1997;  25 927-933
    CrossrefPubMedGoogle Scholar
  • 35 O'Brien C B, Senior J R, Arora-Mirchandani R, Batta A K, Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study.  Hepatology. 1991;  14 838-847
    PubMedGoogle Scholar
  • 36 Beuers U, Spengler U, Kruis W et al.. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial.  Hepatology. 1992;  16 707-714
    CrossrefPubMedGoogle Scholar
  • 37 Lo S K, Hermann R, Chapman R W et al.. Ursodeoxycholic acid in primary sclerosing cholangitis: a double blind placebo controlled trial [abstract].  Hepatology. 1992;  16 92A
    PubMedGoogle Scholar
  • 38 Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann W J, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period.  J Hepatol. 1994;  20 57-64
    CrossrefPubMedGoogle Scholar
  • 39 De Maria N, Colantoni A, Rosenbloom E, Van Thiel D H. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period.  Hepatogastroenterology. 1996;  43 1472-1479
    PubMedGoogle Scholar
  • 40 Lindor K D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group.  N Engl J Med. 1997;  336 691-695
    CrossrefPubMedGoogle Scholar
  • 41 Olsson R G, Boberg K M, Schaffalitzky de Muckadel O et al.. Five year treatment with high dose UDCA in PSC.  J Hepatol. 2004;  40 161 (Abst)
    PubMedGoogle Scholar
  • 42 Hill M J, Melville D M, Lennard-Jones J E, Neale K, Ritchie J K. Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis.  Lancet. 1987;  2 185-186
    PubMedGoogle Scholar
  • 43 Bayerdorffer E, Mannes G A, Richter W O et al.. Increased serum deoxycholic acid levels in men with colorectal adenomas.  Gastroenterology. 1993;  104 145-151
    PubMedGoogle Scholar
  • 44 Stadler J, Yeung K S, Furrer R, Marcon N, Himal H S, Bruce W R. Proliferative activity of rectal mucosa and soluble fecal bile acids in patients with normal colons and in patients with colonic polyps or cancer.  Cancer Lett. 1988;  38 315-320
    CrossrefPubMedGoogle Scholar
  • 45 Reddy B S, Watanabe K, Weisburger J H, Wynder E L. Promoting effect of bile acids in colon carcinogenesis in germ-free and conventional F344 rats.  Cancer Res. 1977;  37 3238-3242
    PubMedGoogle Scholar
  • 46 Ochsenkuhn T, Bayerdorffer E, Meining A et al.. Colonic mucosal proliferation is related to serum deoxycholic acid levels.  Cancer. 1999;  85 1664-1669
    CrossrefPubMedGoogle Scholar
  • 47 Rodrigues C M, Fan G, Wong P Y, Kren B T, Steer C J. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production.  Mol Med. 1998;  4 165-178
    PubMedGoogle Scholar
  • 48 Martinez J D, Stratagoules E D, LaRue J M et al.. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation.  Nutr Cancer. 1998;  31 111-118
    PubMedGoogle Scholar
  • 49 Tung B Y, Emond M J, Haggitt R C et al.. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.  Ann Intern Med. 2001;  134 89-95
    CrossrefPubMedGoogle Scholar
  • 50 Wolf J M, Rybicki L, BA L. Ursodeoxycholic acid is not chemoprotective for colorectal cancer in ulcerative colitis patients with primary sclerosing cholangitis [abstract].  Gastroenterology. 2001;  121 2276
    PubMedGoogle Scholar
  • 51 Pardi D S, Loftus Jr E V, Kremers W K, Keach J, Lindor K D. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.  Gastroenterology. 2003;  124 889-893
    CrossrefPubMedGoogle Scholar
  • 52 van Hoogstraten H J, Wolfhagen F H, van de Meeberg P C et al.. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses.  J Hepatol. 1998;  29 417-423
    CrossrefPubMedGoogle Scholar
  • 53 Mitchell S A, Bansi D S, Hunt N, Von Bergmann K, Fleming K A, Chapman R W. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.  Gastroenterology. 2001;  121 900-907
    CrossrefPubMedGoogle Scholar
  • 54 Harnois D M, Angulo P, Jorgensen R A, Larusso N F, Lindor K D. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.  Am J Gastroenterol. 2001;  96 1558-1562
    CrossrefPubMedGoogle Scholar
  • 55 Okolicsanyi L, Groppo M, Floreani A et al.. Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey.  Dig Liver Dis. 2003;  35 325-331
    CrossrefPubMedGoogle Scholar
  • 56 Burgert S L, Brown B P, Kirkpatrick R B, LaBrecgue D R. Positive corticosteroid response in early primary sclerosing cholangitis [abstract].  Gastroenterology. 1984;  86 1037
    PubMedGoogle Scholar
  • 57 Sivak Jr M V, Farmer R G, Lalli A F. Sclerosing cholangitis: its increasing frequency of recognition and association with inflammatory bowel disease.  J Clin Gastroenterol. 1981;  3 261-266
    PubMedGoogle Scholar
  • 58 Lindor K D, Wiesner R H, Colwell L J, Steiner B, Beaver S, LaRusso N F. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis.  Am J Gastroenterol. 1991;  86 57-61
    PubMedGoogle Scholar
  • 59 Angulo P, Batts K P, Jorgensen R A, LaRusso N A, Lindor K D. Oral budesonide in the treatment of primary sclerosing cholangitis.  Am J Gastroenterol. 2000;  95 2333-2337
    CrossrefPubMedGoogle Scholar
  • 60 Grijm R, Huibregtse K, Bartelsman J, Mathus-Vliegen E M, Dekker W, Tytgat G N. Therapeutic investigations in primary sclerosing cholangitis.  Dig Dis Sci. 1986;  31 792-798
    CrossrefPubMedGoogle Scholar
  • 61 Jeffrey G P, Reed W D, Laurence B H, Shilkin K B. Primary sclerosing cholangitis: clinical and immunopathological review of 21 cases.  J Gastroenterol Hepatol. 1990;  5 135-140
    PubMedGoogle Scholar
  • 62 Craig P I, Willaims S J, Hatfield A RW, Ng M, PB C. Endoscopic management of primary sclerosing cholangitis [abstract].  Gut. 1990;  31 1182
    PubMedGoogle Scholar
  • 63 Allison M C, Burroughs A K, Noone P, Summerfield J A. Biliary lavage with corticosteroids in primary sclerosing cholangitis. A clinical, cholangiographic and bacteriological study.  J Hepatol. 1986;  3 118-122
    CrossrefPubMedGoogle Scholar
  • 64 Boberg K M, Egeland T, Schrumpf E. Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients.  Scand J Gastroenterol. 2003;  38 991-995
    CrossrefPubMedGoogle Scholar
  • 65 Nakazawa T, Ohara H, Sano H et al.. Clinical differences between primary sclerosing cholangitis and sclerosing cholangitis with autoimmune pancreatitis.  Pancreas. 2005;  30 20-25
    PubMedGoogle Scholar
  • 66 Tjandra K, Le T, Swain M G. Glucocorticoid receptors are downregulated in hepatic T lymphocytes in rats with experimental cholangitis.  Gut. 2003;  52 1363-1370
    CrossrefPubMedGoogle Scholar
  • 67 Knox T A, Kaplan M M. Treatment of primary sclerosing cholangitis with oral methotrexate.  Am J Gastroenterol. 1991;  86 546-552
    PubMedGoogle Scholar
  • 68 Knox T A, Kaplan M M. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis.  Gastroenterology. 1994;  106 494-499
    CrossrefPubMedGoogle Scholar
  • 69 Lindor K D, Jorgensen R A, Anderson M L, Gores G J, Hofmann A F, LaRusso N F. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study.  Am J Gastroenterol. 1996;  91 511-515
    PubMedGoogle Scholar
  • 70 Sandborn W J, Wiesner R H, Tremaine W J, Larusso N F. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin.  Gut. 1993;  34 242-246
    CrossrefPubMedGoogle Scholar
  • 71 Kyokane K, Ichihara T, Horisawa M et al.. Successful treatment of primary sclerosing cholangitis with cyclosporine and corticosteroid.  Hepatogastroenterology. 1994;  41 449-452
    PubMedGoogle Scholar
  • 72 Van Thiel D H, Carroll P, Abu-Elmagd K et al.. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial.  Am J Gastroenterol. 1995;  90 455-459
    PubMedGoogle Scholar
  • 73 Sterling R K, Salvatori J J, Luketic V A et al.. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis.  Aliment Pharmacol Ther. 2004;  20 943-949
    CrossrefPubMedGoogle Scholar
  • 74 Wagner A. Azathioprine treatment in primary sclerosing cholangitis.  Lancet. 1971;  2 663-664
    PubMedGoogle Scholar
  • 75 Javett S L. Azathioprine in primary sclerosing cholangitis.  Lancet. 1971;  1 810
    PubMedGoogle Scholar
  • 76 Duchini A, Younossi Z M, Saven A, Bordin G M, Knowles H J, Pockros P J. An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis.  J Clin Gastroenterol. 2000;  31 292-296
    CrossrefPubMedGoogle Scholar
  • 77 Bharucha A E, Jorgensen R, Lichtman S N, LaRusso N F, Lindor K D. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis.  Am J Gastroenterol. 2000;  95 2338-2342
    CrossrefPubMedGoogle Scholar
  • 78 Epstein M P, Kaplan M M. A pilot study of etanercept in the treatment of primary sclerosing cholangitis.  Dig Dis Sci. 2004;  49 1-4
    CrossrefPubMedGoogle Scholar
  • 79 Schramm C, Schirmacher P, Helmreich-Becker I, Gerken G, zum Buschenfelde K H, Lohse A W. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series.  Ann Intern Med. 1999;  131 943-946
    PubMedGoogle Scholar
  • 80 Vierling J. Aetiopathogenesis of primary sclerosing cholangitis. In: Manns P, Stieihl A, Wiesner R Primary Sclerosing Cholangitis. London; Kluwer Academic Publishers 1998: 9
    Google Scholar
  • 81 Farkkila M, Karvonen A L, Nurmi H et al.. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.  Hepatology. 2004;  40 1379-1386
    CrossrefPubMedGoogle Scholar
  • 82 Angulo P, MacCarty R L, Sylvestre P B et al.. Pirfenidone in the treatment of primary sclerosing cholangitis.  Dig Dis Sci. 2002;  47 157-161
    CrossrefPubMedGoogle Scholar
  • 83 Olsson R, Broome U, Danielsson A et al.. Colchicine treatment of primary sclerosing cholangitis.  Gastroenterology. 1995;  108 1199-1203
    CrossrefPubMedGoogle Scholar
  • 84 Ball K R, Kowdley K V. A review of Silybum marianum (milk thistle) as a treatment for alcoholic liver disease.  J Clin Gastroenterol. 2005;  39 520-528
    CrossrefPubMedGoogle Scholar
  • 85 Angulo P, Bharucha A E, Jorgensen R A et al.. Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study.  Dig Dis Sci. 1999;  44 602-607
    CrossrefPubMedGoogle Scholar
  • 86 Vleggaar F P, van Buuren H R, van Berge Henegouwen G P, Hop W C, van Erpecum K J. No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study.  Eur J Gastroenterol Hepatol. 2001;  13 171-175
    CrossrefPubMedGoogle Scholar
  • 87 LaRusso N F, Wiesner R H, Ludwig J, MacCarty R L, Beaver S J, Zinsmeister A R. Prospective trial of penicillamine in primary sclerosing cholangitis.  Gastroenterology. 1988;  95 1036-1042
    PubMedGoogle Scholar
  • 88 Gross C R, Malinchoc M, Kim W R et al.. Quality of life before and after liver transplantation for cholestatic liver disease.  Hepatology. 1999;  29 356-364
    CrossrefPubMedGoogle Scholar
  • 89 ter Borg P C, van Os E, van den Broek W W, Hansen B E, van Buuren H R. Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial.  , [ISRCTN88246634] BMC Gastroenterol. 2004;  4 13
    CrossrefPubMedGoogle Scholar
  • 90 Bjornsson E, Simren M, Olsson R, Chapman R W. Fatigue in patients with primary sclerosing cholangitis.  Scand J Gastroenterol. 2004;  39 961-968
    CrossrefPubMedGoogle Scholar
  • 91 Mela M, Mancuso A, Burroughs A K. Review article: pruritus in cholestatic and other liver diseases.  Aliment Pharmacol Ther. 2003;  17 857-870
    CrossrefPubMedGoogle Scholar
  • 92 Bergasa N V, Jones E A. The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids.  Gastroenterology. 1995;  108 1582-1588
    CrossrefPubMedGoogle Scholar
  • 93 Richardson B P. Serotonin and nociception.  Ann NY Acad Sci. 1990;  600 511-520
    CrossrefPubMedGoogle Scholar
  • 94 Thornton J R, Losowsky M S. Opioid peptides and primary biliary cirrhosis.  BMJ. 1988;  297 1501-1504
    PubMedGoogle Scholar
  • 95 Bergasa N V, Talbot T L, Alling D W et al.. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis.  Gastroenterology. 1992;  102 544-549
    PubMedGoogle Scholar
  • 96 Bergasa N V, Schmitt J M, Talbot T L et al.. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis.  Hepatology. 1998;  27 679-684
    CrossrefPubMedGoogle Scholar
  • 97 Wolfhagen F H, Sternieri E, Hop W C, Vitale G, Bertolotti M, Van Buuren H R. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study.  Gastroenterology. 1997;  113 1264-1269
    CrossrefPubMedGoogle Scholar
  • 98 Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron.  Pain. 1995;  61 33-37
    CrossrefPubMedGoogle Scholar
  • 99 Muller C, Pongratz S, Pidlich J et al.. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial.  Eur J Gastroenterol Hepatol. 1998;  10 865-870
    PubMedGoogle Scholar
  • 100 Ghent C N, Carruthers S G. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial.  Gastroenterology. 1988;  94 488-493
    PubMedGoogle Scholar
  • 101 Podesta A, Lopez P, Terg R et al.. Treatment of pruritus of primary biliary cirrhosis with rifampin.  Dig Dis Sci. 1991;  36 216-220
    CrossrefPubMedGoogle Scholar
  • 102 Bachs L, Pares A, Elena M, Piera C, Rodes J. Effects of long-term rifampicin administration in primary biliary cirrhosis.  Gastroenterology. 1992;  102 2077-2080
    CrossrefPubMedGoogle Scholar
  • 103 Woolf G M, Reynolds T B. Failure of rifampin to relieve pruritus in chronic liver disease.  J Clin Gastroenterol. 1990;  12 174-177
    PubMedGoogle Scholar
  • 104 Miguet J P, Mavier P, Soussy C J, Dhumeaux D. Induction of hepatic microsomal enzymes after brief administration of rifampicin in man.  Gastroenterology. 1977;  72 924-926
    PubMedGoogle Scholar
  • 105 Berg C L, Gollan J L. Primary biliary cirrhosis: new therapeutic directions.  Scand J Gastroenterol Suppl. 1992;  192 43-49
    PubMedGoogle Scholar
  • 106 Angulo P, Therneau T M, Jorgensen A et al.. Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression.  J Hepatol. 1998;  29 729-735
    CrossrefPubMedGoogle Scholar
  • 107 Campbell M S, Lichtenstein G R, Rhim A D, Pazianas M, Faust T. Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitis.  Liver Int. 2005;  25 311-316
    CrossrefPubMedGoogle Scholar
  • 108 Jorgensen R A, Lindor K D, Sartin J S, LaRusso N F, Wiesner R H. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis.  J Clin Gastroenterol. 1995;  20 215-219
    PubMedGoogle Scholar

Roger W ChapmanM.D. 

John Radcliffe Hospital, Head ley Way, Heading ham, Oxford OX3 9DU, United Kingdom

Email: roger.chapman@clinical-medicine.oxford.ac.uk

      >